armh3 Antibody

What is ARMH3 protein and what are its key biological characteristics?

ARMH3 (Armadillo-like helical domain-containing protein 3) is a protein involved in GBF1 recruitment, Golgi maintenance and protein secretion. In humans, the canonical protein has 689 amino acid residues with a molecular mass of 78.7 kDa. Up to three different isoforms have been reported for this protein, which is widely expressed in many tissue types . It is primarily localized to the Golgi apparatus membrane and cytoplasm, with the majority being cytosolic and a portion colocalizing with GBF1 at juxtanuclear Golgi sites .

ARMH3 is also known by synonyms including armadillo-like helical domain-containing protein 3 and UPF0668 protein C10orf76. Notably, ARMH3 gene orthologs have been identified across multiple species including mouse, rat, bovine, frog, zebrafish, chimpanzee and chicken .

What applications are ARMH3 antibodies most commonly used for in research settings?

ARMH3 antibodies are predominantly employed in immunodetection of the armadillo like helical domain containing 3 protein. The most widely used applications include:

Western Blot remains the most established technique for ARMH3 detection, with most commercial antibodies validated for this application .

How should researchers select the appropriate ARMH3 antibody for their specific experimental system?

When selecting an ARMH3 antibody, researchers should consider multiple factors:

• Species reactivity: Determine whether the antibody recognizes ARMH3 in your model system. Available antibodies show varying reactivity patterns, from narrow human-specific recognition to broader cross-species reactivity including human, mouse, rabbit, rat, dog, horse, pig and zebrafish .

• Target epitope: Consider which region of ARMH3 the antibody recognizes. Some commercial antibodies target the C-terminal region, while others recognize specific amino acid ranges such as 135-185 . This is particularly important when studying specific isoforms.

• Validated applications: Ensure the antibody is validated for your intended application. Most ARMH3 antibodies are validated for Western Blot, but confirm validation for other techniques like IHC if needed .

• Antibody format: Determine whether you need unconjugated antibodies (most common for ARMH3) or specific conjugates for specialized applications .

• Clonality: Consider whether polyclonal (offering multiple epitope recognition) or monoclonal (higher specificity) antibodies better suit your experimental needs. Most available ARMH3 antibodies are polyclonal, particularly rabbit polyclonal .

What are the optimized Western Blot protocols for detecting ARMH3 protein?

For optimal ARMH3 detection via Western Blot, researchers should implement the following protocol:

• Sample preparation: Extract proteins using RIPA buffer supplemented with protease inhibitors. ARMH3's Golgi association may require careful lysis optimization.

• Protein separation: Use 8-10% SDS-PAGE gels to effectively resolve ARMH3's ~78.7 kDa mass.

• Transfer conditions: Transfer proteins to PVDF membranes (preferred over nitrocellulose for this molecular weight) at 100V for 1-2 hours or 30V overnight at 4°C.

• Blocking: Block membranes with 5% BSA in TBST (preferred over milk for this application).

• Primary antibody: Dilute ARMH3 antibody at 1:500-2000 in blocking buffer and incubate overnight at 4°C .

• Detection: Use HRP-conjugated secondary antibodies and enhanced chemiluminescence for visualization.

• Expected results: Anticipate a primary band at approximately 78.7 kDa, with possible additional bands representing the different isoforms reported for this protein .

How can researchers effectively optimize immunohistochemistry protocols for ARMH3 detection in tissue samples?

Optimizing IHC for ARMH3 requires careful consideration of several parameters:

• Fixation: Use 10% neutral buffered formalin or 4% paraformaldehyde for 24-48 hours, as over-fixation may mask epitopes relevant to ARMH3 detection.

• Antigen retrieval: This critical step typically requires heat-induced epitope retrieval with citrate buffer (pH 6.0) or EDTA buffer (pH 9.0). Both methods should be tested to determine optimal retrieval conditions for ARMH3.

• Blocking: Block endogenous peroxidase activity with 3% H₂O₂, followed by protein blocking with 5-10% normal serum from the same species as the secondary antibody.

• Primary antibody incubation: Apply ARMH3 antibody at optimized dilution (typically starting at manufacturer's recommendation) and incubate overnight at 4°C in a humidified chamber.

• Detection system: Use a polymer-based detection system for enhanced sensitivity with minimal background.

• Expected staining pattern: Look for ARMH3 localization primarily in the Golgi apparatus and cytoplasm . Patterns may vary by tissue type due to ARMH3's wide expression profile.

• Counterstaining: Use hematoxylin for nuclear counterstaining to provide cellular context for ARMH3 expression patterns.

What controls are essential when conducting experiments with ARMH3 antibodies?

Rigorous experimental design with ARMH3 antibodies requires multiple controls:

• Positive controls: Include tissues or cell lines with documented ARMH3 expression. Given ARMH3's wide tissue distribution, human cell lines such as HeLa or HEK293 cells often serve as reliable positive controls .

• Negative controls:

  • Antibody omission control: Perform parallel staining without primary antibody

  • Isotype control: Use matched concentration of non-specific IgG

  • Biological negative controls: When available, use ARMH3 knockout/knockdown samples

• Epitope competition: Consider performing peptide competition assays using the immunizing peptide to confirm antibody specificity.

• Cross-validation: Use multiple antibodies targeting different ARMH3 epitopes to verify detection patterns.

• Loading/processing controls: For Western blot, include appropriate housekeeping proteins; for IHC, process control tissues alongside experimental samples.

These controls collectively enhance experimental rigor and support valid interpretation of ARMH3 detection results.

How can researchers differentiate between the reported isoforms of ARMH3 in experimental systems?

Distinguishing between the three reported isoforms of ARMH3 requires a strategic approach:

• Antibody selection strategy: Choose antibodies targeting regions that differ between isoforms or use multiple antibodies targeting different epitopes. Some commercial antibodies specifically target the C-terminal region while others target amino acids 135-185 .

• Gel electrophoresis optimization: Employ gradient gels (4-15%) with extended running times to resolve closely migrating isoforms. Precision Plus protein standards should be used for accurate molecular weight determination.

• Two-dimensional electrophoresis: This technique separates proteins based on both isoelectric point and molecular weight, potentially distinguishing isoforms with post-translational modifications.

• RT-PCR validation: Design primers specific to each isoform's unique regions to confirm expression at the mRNA level.

• Recombinant protein standards: Express and purify each ARMH3 isoform individually to serve as migration standards.

• Mass spectrometry analysis: For definitive identification, employ LC-MS/MS to identify unique peptides specific to each isoform.

What methodological approaches can effectively investigate ARMH3's role in Golgi maintenance and protein secretion?

To study ARMH3's functional role in Golgi maintenance and protein secretion , researchers should consider these methodological approaches:

• Co-localization studies:

  • Dual immunofluorescence with ARMH3 antibodies and Golgi markers

  • Super-resolution microscopy to precisely map ARMH3 distribution relative to Golgi subcompartments

  • Live-cell imaging with fluorescently tagged ARMH3 to track dynamic localization

• Functional perturbation experiments:

  • siRNA or CRISPR-Cas9 mediated ARMH3 knockdown/knockout

  • Domain-specific mutant expression to identify functional regions

  • Rescue experiments with wild-type ARMH3 in depleted cells

• Protein-protein interaction analysis:

  • Co-immunoprecipitation using ARMH3 antibodies to identify binding partners

  • Proximity ligation assays to confirm in situ interactions

  • FRET/BRET analyses for studying dynamic interactions

• Secretion assays:

  • Pulse-chase experiments tracking cargo proteins in ARMH3-depleted cells

  • Quantification of secreted proteins using reporter systems

  • Live-cell imaging of secretory vesicle trafficking

How can computational modeling approaches enhance ARMH3 antibody development and applications?

Building on principles from antibody-recruiting molecule research , computational modeling offers several advantages for ARMH3 antibody research:

• Epitope prediction and optimization:

  • Structural modeling of ARMH3 to identify accessible, unique epitopes

  • Simulation of antibody-epitope interactions to predict binding affinity

  • Molecular dynamics simulations to account for protein flexibility

• Antibody design parameters:

  • Optimization of spacer length between binding domains for multivalent antibodies

  • Selection of optimal molecular scaffolds for engineered antibodies

  • Prediction of how modifications affect antibody characteristics

• Cross-reactivity prediction:

  • In silico analysis of epitope conservation across species

  • Comparison with human proteome to minimize off-target binding

  • Identification of epitopes unique to specific ARMH3 isoforms

• Application-specific design:

  • Modeling effects of conjugation (e.g., fluorophores) on binding properties

  • Prediction of antibody fragment stability for specialized applications

  • Optimization of antibody properties for specific experimental conditions

Computational approaches allow researchers to rationally design antibodies with enhanced specificity, optimized binding properties, and application-specific characteristics, significantly accelerating research progress .

What are common technical challenges in ARMH3 detection and how can researchers overcome them?

Researchers frequently encounter these challenges when working with ARMH3 antibodies:

How should researchers interpret variations in ARMH3 expression and localization across different experimental conditions?

When analyzing ARMH3 expression and localization data, consider these interpretation frameworks:

• Baseline expression analysis:

  • Establish reference expression levels in relevant control tissues/cells

  • ARMH3 is widely expressed across many tissue types , so tissue-specific patterns require careful normalization

  • Quantify both total protein levels and subcellular distribution

• Comparative analysis methodology:

  • Apply consistent quantification methods across samples

  • Use appropriate statistical tests for expression differences

  • Normalize to established housekeeping genes/proteins suitable for the specific tissue/cell type

• Localization pattern assessment:

  • Normal ARMH3 localization includes Golgi and cytoplasm

  • Changes in subcellular distribution may indicate altered function

  • Quantify co-localization with Golgi markers using appropriate coefficients (Pearson's, Manders')

• Physiological context interpretation:

  • Connect ARMH3 changes to its known functions in GBF1 recruitment, Golgi maintenance, and protein secretion

  • Consider how experimental manipulations might affect these pathways

  • Relate findings to potential downstream effects on secretory function

How can researchers validate ARMH3 antibody specificity to ensure reliable experimental results?

Comprehensive ARMH3 antibody validation requires multiple approaches:

• Genetic validation strategies:

  • Test antibody in ARMH3 knockout/knockdown models

  • Overexpress tagged ARMH3 and confirm co-detection

  • Use cell lines from species outside the antibody's specified reactivity as negative controls

• Biochemical validation methods:

  • Peptide competition assays using the immunizing peptide

  • Pre-absorption experiments with recombinant ARMH3 protein

  • Testing multiple antibodies against different ARMH3 epitopes

• Orthogonal technique validation:

  • Correlate protein detection with mRNA levels

  • Confirm subcellular localization using fractionation followed by Western blot

  • Validate using mass spectrometry identification of immunoprecipitated proteins

• Application-specific validation:

  • For Western blot: Verify molecular weight and band pattern consistency

  • For IHC/ICC: Confirm expected subcellular localization pattern

  • For IP experiments: Validate pull-down specificity via mass spectrometry

How might ARMH3 antibodies contribute to studying secretory pathway dysregulation in disease models?

ARMH3 antibodies offer valuable tools for investigating secretory pathway alterations in pathological conditions:

• Neurodegenerative disease applications:

  • Track ARMH3 expression/localization changes in models of diseases with known Golgi fragmentation (e.g., ALS, Alzheimer's)

  • Investigate whether ARMH3 dysfunction contributes to protein misfolding and aggregation

  • Examine correlations between ARMH3 status and secretory defects in patient-derived cells

• Cancer research applications:

  • Assess ARMH3 alterations in cancer cells with enhanced secretory capacity

  • Investigate relationships between ARMH3 expression and metastatic potential

  • Explore ARMH3 as a potential biomarker for specific cancer subtypes

• Methodological approaches:

  • Tissue microarray analysis using validated ARMH3 antibodies

  • Live-cell trafficking studies in patient-derived cells

  • Correlative light-electron microscopy for ultrastructural analysis of ARMH3-associated compartments

• Therapeutic exploration:

  • Development of ARMH3-targeted interventions to modulate secretory capacity

  • Screening for compounds that modify ARMH3 function or localization

  • Assessment of ARMH3 status as a predictor of response to secretory pathway-targeting drugs

What role can ARMH3 antibodies play in advanced single-cell and spatial biology research?

Integration of ARMH3 antibodies with cutting-edge single-cell technologies enables several innovative approaches:

• Single-cell proteomic applications:

  • Optimization of ARMH3 antibodies for mass cytometry (CyTOF)

  • Incorporation into single-cell Western blot platforms

  • Development of proximity extension assays for high-sensitivity detection

• Spatial proteomic integration:

  • Inclusion of ARMH3 antibodies in multiplexed immunofluorescence panels

  • Implementation in imaging mass cytometry workflows

  • Correlation of ARMH3 spatial distribution with functional tissue architecture

• Multi-omics integration strategies:

  • Combining ARMH3 protein detection with transcriptomic profiling

  • Correlating ARMH3 status with secretome analysis

  • Integrating ARMH3 data with interactome mapping

• Technology-specific considerations:

  • Antibody conjugation optimization for multiplexed applications

  • Validation of antibody performance in fixation conditions required for specific platforms

  • Development of computational pipelines for integrating ARMH3 data across multiple analytical modalities

How can researchers incorporate ARMH3 antibody-based methods with emerging computational and bioinformatic approaches?

Integration of experimental ARMH3 antibody data with computational methods creates powerful research synergies:

• Machine learning integration:

  • Development of image analysis algorithms for automated ARMH3 localization quantification

  • Pattern recognition in ARMH3 expression data across disease models

  • Predictive modeling of how ARMH3 alterations affect secretory pathway function

• Network analysis applications:

  • Integration of ARMH3 interactome data into protein-protein interaction networks

  • Pathway enrichment analysis incorporating ARMH3 antibody-derived data

  • Systems biology approaches connecting ARMH3 to broader cellular functions

• Structure-function computational studies:

  • Molecular modeling of ARMH3 structure and domain functions

  • Computational prediction of critical ARMH3 binding interfaces

  • In silico screening for molecules that modulate ARMH3 function

• Data visualization and integration platforms:

  • Development of visualization tools for complex ARMH3 localization data

  • Creation of databases integrating ARMH3 expression across tissues and conditions

  • Establishment of standardized analytical pipelines for ARMH3 antibody-generated data

These integrative approaches can accelerate research progress by extracting maximum insights from antibody-based studies and connecting findings to broader biological contexts.